Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) and Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.
Insider and Institutional Ownership
26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Sol-Gel Technologies and Taysha Gene Therapies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sol-Gel Technologies | $12.10 million | 1.70 | -$10.58 million | ($4.70) | -1.57 |
| Taysha Gene Therapies | $7.22 million | 71.32 | -$89.30 million | ($0.34) | -7.06 |
Sol-Gel Technologies has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Sol-Gel Technologies, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Sol-Gel Technologies and Taysha Gene Therapies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sol-Gel Technologies | 0 | 0 | 1 | 0 | 3.00 |
| Taysha Gene Therapies | 0 | 0 | 6 | 0 | 3.00 |
Sol-Gel Technologies currently has a consensus target price of $40.00, indicating a potential upside of 441.27%. Taysha Gene Therapies has a consensus target price of $8.20, indicating a potential upside of 241.67%. Given Sol-Gel Technologies’ higher probable upside, equities analysts plainly believe Sol-Gel Technologies is more favorable than Taysha Gene Therapies.
Profitability
This table compares Sol-Gel Technologies and Taysha Gene Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sol-Gel Technologies | -107.78% | -43.98% | -35.28% |
| Taysha Gene Therapies | -1,201.08% | -104.93% | -50.09% |
Volatility & Risk
Sol-Gel Technologies has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
Summary
Sol-Gel Technologies beats Taysha Gene Therapies on 9 of the 13 factors compared between the two stocks.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
